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1684-1182/Copyright ª 2014, Taiwan
CC BY-NC-ND license (http://creativePurpose: The aim of this study was to estimate the prevalence and antimicrobial susceptibility
of Ureaplasma urealyticum and Mycoplasma hominis among female outpatients treated for
genital infection at a Chinese hospital from January 1, 2009 to December 31, 2013.
Methods: Samples from 6051 female outpatients were analyzed using Mycoplasma Identifica-
tion and Antimicrobial Susceptibility Testing (ID/AST).
Results: The overall prevalence of U. urealyticum was higher than the prevalence of single M.
hominis infection (31.2% vs 0.7%) and coinfections (31.2% vs. 1.9%). The percentage of U. urea-
lyticum and/or M. hominis detected in the 30e39 year age group was greater than in the other
age groups. More than 94.6% of the U. urealyticum isolates, 100% of theM. hominis isolates, and
84.3% of the isolates from coinfections were susceptible to doxycycline, minocycline, and tetra-
cycline. More than 69.2% of the U. urealyticum isolates were susceptible to azithromycin, eryth-
romycin, clarithromycin, and roxithromycin, but> 95.6% of theM. hominis isolates and 89.6% of
the isolates from coinfections were resistant to these antibiotics. Acetylspiramycin, sparfloxa-
cin, levofloxacin, ciprofloxacin, and ofloxacin were inactive against more than one-half of the
isolates. More than 75.6% of the M. hominis isolates were susceptible to spectinomycin, but
> 87.1% of the U. urealyticum and 93.3% of the coinfection isolates were resistant to this antibi-
otic. Isolates from three coinfections were completely resistant to the 14 antibiotics.
Conclusion: The determination of antimicrobial susceptibility of these mycoplasma species is
often crucial for optimal antimicrobial therapy of infected outpatients.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Ample evidence from clinical studies using culture,
serology, and polymerase chain reaction (PCR) assays in
humans, and from experimental infection of laboratory
animals indicates that Ureaplasma urealyticum and Myco-
plasma hominis are etiologic agents of a variety of uro-
genital diseases in women. These diseases include urinary
calculus formation, pyelonephritis, bacterial vaginosis,
pelvic inflammatory disease, infertility, chorioamnionitis,
spontaneous abortion, prematurity, intrauterine growth
retardation, postpartum fever, and extragenital disease.1
Antibiotic resistance among urogenital mycoplasmas de-
velops via gene mutation or the acquisition of new genetic
material. The prevalence of these pathogens and the re-
sults of surveillance of their antibiotic resistance profiles
change in relation to the patient’s country of origin. Testing
should be performed for optimal antimicrobial therapy of
infected patients, and to monitor the spread of resistant
organisms.2e4 Some related research studies have been
performed in China. However, the resistance characteris-
tics were different and may be related to local antibiotic
use regulations. It is important to perform a detailed
analysis on the characteristics of the area in which the
resistant strains occur. The aim of this study was to esti-
mate the prevalence of U. urealyticum and M. hominis in-
fections and the antimicrobial susceptibilities of isolates of
these bacteria. Analyses of patient age groups and some
multidrug-resistant strains were also included.
Materials and methods
Between January 1, 2009 and December 31, 2013, a total of
6051 specimens were examined by the Department of
Clinical Laboratory at the Xiyuan Hospital, China Academy
of Chinese Medical Sciences (Beijing, China). Consistent
with the manufacturers’ guidelines and standard laboratory
protocols, all specimens were immediately transported to
the laboratory without additional transport medium. They
were then refrigerated and examined within 48 hours after
collection. The microbiological principle used by Myco-
plasma identification verification and antibiotic suscepti-
bility testing kits was as follows: during growth, U.
urealyticum and M. hominis metabolize urea and arginine,
respectively, which changes the color of the culture me-
dium (e.g., from yellow to red). Susceptibility results were
obtained at two concentrations for 14 antibiotics: eryth-
romycin, acetylspiramycin, josamycin, tetracycline, doxy-
cycline, minocycline, roxithromycin, levofloxacin,
ofloxacin, azithromycin, clarithromycin, sparfloxacin, cip-
rofloxacin, and spectinomycin. The three possible results
were “susceptible”, “intermediate”, and “resistant”. Bac-
terial growth was evaluated after a 2-day incubation period
(at 37C). The results were interpreted as follows: a
negative result was clear and a color change of more than
104 units was evidence of infection. Clinical and Laboratory
Standards Institute (CLSI) guidelines were used to catego-
rize the results for bacterial susceptibility or resistance to
antibiotics.2,5 The breakpoints for the 14 antibiotics (mg/L)
were: erythromycin, S  1, R  4; acetylspiramycin, S  1,
R  2; josamycin, S  2, R  8; tetracycline, S  4, R  8;doxycycline, S  4, R  8; minocycline, S  4, R  8; rox-
ithromycin, S  1, R  4; levofloxacin, S  1, R  4;
ofloxacin, S  1, R  4; azithromycin, S  0.12, R  4;
clarithromycin, S  1, R  4; sparfloxacin, S  1, R  4;
ciprofloxacin, S  1, R  2; and spectinomycin, S  4, R  8.
For all analyses, p < 0.05 indicated statistical significance.
Ethics Committee approval and informed patient consent
were not required for this study.
Results
The total positive rate of infection for the 6051 female
outpatients was 33.9% (Table 1). The overall prevalence of
U. urealyticum infection was greater than the prevalence
of M. hominis infection (31.2% vs. 0.7%) and was greater
than the prevalence of coinfection (31.2% vs. 1.9%).
The results for the distribution of M. hominis and U.
urealyticum, according to age group, are presented in
Table 1. During our study period, 49.7% of positive results
occurred in the 30e39 year age group, which was signifi-
cantly higher in comparison to the other age groups
(p < 0.05).
There was no resistance to any of the three tetracyclines
(i.e., tetracycline, doxycycline, and minocycline) for any
M. hominis isolate, and 91.1% of these isolates were sus-
ceptible to the macrolide josamycin. These four antibiotics
were also effective against > 87.9% of the U. urealyticum
isolates and 73% of the bacteria isolated from coinfections.
More than 95.6% of the M. hominis isolates and 89.6% of the
isolates from coinfections were resistant to four of the
macrolide antibiotics (i.e., azithromycin, erythromycin,
clarithromycin, roxithromycin), but > 69.2% of the U. ure-
alyticum isolates were susceptible to these antibiotics.
More than 50% of the bacteria isolated from the study
population were resistant to four of the quinolone antibi-
otics (i.e., sparfloxacin, levofloxacin, ciprofloxacin, and
ofloxacin) and one of the macrolide antibiotics (i.e., ace-
tylspiramycin). The bacteria isolated from three of the
coinfections (i.e., U. urealyticum and M. hominis) were
completely (100%) resistant to the 14 antibiotics.
Discussion
Mycoplasmas are the smallest free-living microorganisms.
They are commonly isolated from the genitourinary tract of
symptomatic patients, but also from asymptomatic pa-
tients. The aim of this study was to evaluate differences in
the prevalence and antibiotic resistance of U. urealyticum
and M. hominis. Single infections with U. urealyticum were
most prevalent (31.2%), followed by coinfections with U.
urealyticum and M. hominis (1.9%) and single infections
with M. hominis (0.7%). The infection rate was significantly
higher in young women than in older women. This result is
consistent with results reported in other studies.5e7 Except
for age and sex distribution of the outpatients, no other
demographic or clinical characteristics were examined in
this study. Other characteristics will be examined in a
follow-up study.
Mycoplasmas are normally susceptible to antibiotics that
inhibit protein synthesis, but are resistant to antibiotics
that act on bacterial cell wall components because
Table 1 Distribution of Ureaplasma urealyticum and Mycoplasma hominis (single infection and coinfection) among female
outpatients in different age groups during the study perioda
Infection in different
age groups
Ureaplasma
urealyticum
Mycoplasma
hominis
Coinfection Negative Total
20e29 718 (32.8) 15 (0.7) 47 (2.1) 1408 (64.4) 2188 (100)
30e39 948 (29.6) 24 (0.7) 46 (1.4) 2189 (68.3) 3207 (100)
40e49 193 (34.4) 4 (0.7) 19 (3.4) 345 (61.5) 561 (100)
Others 30 (31.6) 2 (2.1) 3 (3.2) 60 (63.2) 95 (100)
Total 1889 (31.2) 45 (0.7) 115 (1.9) 4002 (66.1) 6051 (100)
a “Coinfection” means that the patients were simultaneously infected with Ureaplasma urealyticum and Mycoplasma hominis.
Data are presented as n (%).
Table 2 Antimicrobial susceptibility of Ureaplasma ure-
alyticum and Mycoplasma hominis (single and coinfection)
to 14 antibiotics among female outpatients during the study
perioda
Antibiotic U. urealyticum M. hominis Coinfection
Spectinomycin 12.9 75.6 6.7
Tetracycline 95.2 100 84.3
Minocycline 94.6 100 85.2
Doxycycline 98 100 88.7
Ciprofloxacin 5.8 17. 8 5.2
Ofloxacin 22.1 15. 6 10.4
Sparfloxacin 43.1 37. 8 27
Levofloxacin 39.9 20 20
Azithromycin 69.2 2.2 4.3
Erythromycin 78.1 0 0
Josamycin 87.9 91.1 73
Roxithromycin 96.5 4.4 7.8
Acetylspiramycin 31.7 35.6 9.6
Clarithromycin 98.4 4.4 10.4
a “Coinfection” means that the patients were simultaneously
infected with Ureaplasma urealyticum and Mycoplasma
hominis.
Data are presented as %.
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study indicated that there was a difference in sensitivity to
14 antibiotics among the isolates from single infections and
from the coinfections. Three tetracycline antibiotics (i.e.,
tetracycline, doxycycline, and minocycline) and one mac-
rolide antibiotic (i.e., josamycin) were active against most
of the strains. However, four of the quinolone antibiotics
(i.e., sparfloxacin, levofloxacin, ciprofloxacin, and oflox-
acin) and one macrolide antibiotic (i.e., acetylspiramycin)
were inactive against more than one-half of the strains
isolated in this study. Four macrolide antibiotics (i.e., azi-
thromycin, erythromycin, clarithromycin, and roxi-
thromycin) were effective against most U. urealyticum
isolates, but were ineffective against most bacteria iso-
lated from the single M. hominis and coinfections. M.
hominis is intrinsically resistant to erythromycin, which was
a characteristic we observed in our results. Our results also
indicated that, except for spectinomycin, the patterns of
antimicrobial susceptibilities against coinfection were
similar to the patterns displayed by M. hominis. Our results
indicate that tetracycline, doxycycline, minocycline, and
josamycin are the first choice drugs when empirical therapy
is required (Table 2). The prevalence of the U. urealyticum
and M. hominis antibiotic resistance profiles in our study
differ from profiles reported by authors of similar
studies.6,7,9 The discrepancies in antimicrobial susceptibil-
ities of isolates from various countries are most likely due
to differences in antimicrobial use policies.2 The results of
our study indicated that three tetracycline antibiotics (i.e.,
tetracycline, doxycycline, and minocycline) and one mac-
rolide antibiotic (i.e., josamycin) represent the options for
initial empirical treatment. The use of erythromycin must
be carefully considered.
Mycoplasmas are innately resistant to penicillins, ri-
fampicins, and some other antibiotics. Some may develop
resistance via gene mutation, acquisition of a resistance
gene, or while being protected by biofilms. Multidrug-
resistant mycoplasma strains have recently been identi-
fied.8,10,11 In our hospital setting, some clinical strains have
developed resistance to the 14 drugs (including the 3
resistant mixed isolates in our study), which has increased
the difficulty of successfully treating mycoplasma in-
fections. Further study of the efficacy of the use of Chinese
medicinal herbs for these infections may result in the dis-
covery of new treatment options.12,13
The detection methods for Mycoplasma include culture,
antigen detection, molecular techniques, and antibodydetection. Methods for the simultaneous detection of U.
urealyticum, M. hominis, and other pathogens are
extremely useful in a clinical setting arena. Examples of
these methods include fluorescence polarization assay,
PCR, and multiplex PCR.14e18 However, although these as-
says may be useful for detecting coinfections in a hospital
setting, they are not useful for detailed information about
antibiotic resistance. The commercial mycoplasma kit used
in this study was more cost-effective and simpler to use
than these methods. However, a limitation of the com-
mercial kit is that it only detects U. urealyticum and M.
hominis; therefore, the development of similar methods for
the simultaneous detection of multiple genitourinary in-
fections would be extremely beneficial. Novel and
improved technologies may be available in the near future.
The emergence of extensively drug-resistant strains of
Mycoplasma means that antibiotic susceptibility testing is
even more important in scientific research and in the clin-
ical setting.19 Mycoplasma identification verification and
antibiotic susceptibility testing in the hospital was per-
formed in 2009. So it was important for us to
362 Q.-Y. Wang et al.retrospectively review the computerized database of the
Clinical Microbiology Laboratory for the study period. The
retrospective analytical approach can effectively provide
clinicians with real data about the rational use of antibi-
otics. We firmly believe that Mycoplasma culture verifica-
tion and antibiotic susceptibility testing will be useful to
avoid treatment failure and abuse of antimicrobial agents.Conflicts of interest
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